![]() |
|
|
Vol. 59, Issue 1, 127-134, January 2001
Department of Biochemistry and Molecular Biology, Faculty of Chemistry, University of Barcelona, Barcelona, Spain (C.H., V.C., F.C., J.M., C.L., R.F.); and the Neurobiology Division, Garvan Institute, Darlinghurst, Australia (P.S.)
| |
Abstract |
|---|
|
|
|---|
Adenosine deaminase (ADA) is an enzyme of the purine metabolism that
has been largely considered to be cytosolic. Recently, it has been
demonstrated that the enzyme appears on the surface of lymphocytes
where it interacts with the T-cell activation antigen CD26. ADA also
appears on the surface of nonlymphoid cells anchored to adenosine
A1 receptors. Here it is demonstrated that cell surface ADA
in ADA+/CD26
T lymphocytes anchors to
adenosine receptors of the A2B subtype (A2BR).
An interaction between A2BR and cell surface ADA has been demonstrated in transfected Chinese hamster ovary cells and Jurkat J32
T lymphocytes. This has been proved by coimmunoprecipitation, binding
of exogenous ADA to A2BR+ cells, and
coimmunolocalization. The specificity of the interaction has also been
demonstrated by the lack of interaction with other members of the G
protein-coupled receptor superfamily. Binding of ADA to
A2BR increases the affinity of the agonist
5'-N-ethylcarboxamidoadenosine and cAMP production. This
effect occurs even when ADA devoid of enzyme activity is used.
Therefore, in lymphocytes, cell surface ADA, apart from degrading
extracellular adenosine, regulates those actions of adenosine that are
mediated via adenosine receptors of the A2B subtype.
| |
Introduction |
|---|
|
|
|---|
The
key role of adenosine in the development and function of the immune
system is demonstrated in the severe combined immunodeficiency syndrome
(SCID) associated with the congenital defect of adenosine deaminase,
the enzyme that degrades the nucleoside [reviewed by Hershfield and
Mitchell (1989)
]. Adenosine deaminase (ADA; E.C. 3.5.4.4) catalyzes
the hydrolytic deamination of adenosine and 2'-deoxyadenosine to
inosine and 2'-deoxyinosine, respectively. Although the location of the
enzyme is mainly cytosolic, ADA is also found associated to the outer
face of the plasma membrane. ADA has been cloned, and the amino acidic
sequence does not contain any signal peptide or transmembrane domain
[see Franco et al. (1997a
,b
) for review]. In lymphocytes, Kameoka et
al. (1993)
have reported that the activation marker CD26, also known as
dipeptidyl peptidase IV, binds ADA to the cell surface. In nonlymphoid
cells, we have identified the A1 adenosine
receptor (A1R) as another cell surface
ADA-anchoring protein (Ciruela et al., 1996
).
The mechanism whereby the ADA-associated SCID affects lymphoid cells is
not completely understood, but recently it has been suggested that
signaling through adenosine receptors in lymphocytes and lymphocyte
precursors contributes to the pathogenesis (Apasov et al., 1997
; Resta
and Thompson, 1997
). Four adenosine receptors, which belong to the
superfamily of heptaspanning receptors coupled to G proteins have been
cloned (A1, A2A,
A2B, and A3) (Ralevic and
Burnstock, 1998
). In lymphocytes, adenosine analogs produce an
accumulation of intracellular cAMP, suggesting that the adenosine receptors expressed are of the A2 subtype and not
of the A1 subtype (Nordstedt et al., 1987
).
Adenosine, acting through A2 adenosine receptors
(A2Rs), regulates the T cell receptor-triggered
activation-related events such as cell proliferation, interleukin-2
production, up-regulation of interleukin-2 receptor
-chain (CD25),
and lymphocyte-mediated cytolysis (Wolberg et al., 1975
; Dos Reis et
al., 1986
; Antonysamy et al., 1995
; Huang et al., 1997
).
A2ARs are involved in adenosine-mediated inhibition of murine T cell activation and expansion (Huang et al.,
1997
). A2BRs are up-regulated, elicit significant
reductions in interleukin-2 production in activated human T cell
(Mirabet et al., 1999
), and contribute to the deactivation of
macrophages, because they reduce the interferon-
-induced
up-regulation of major histocompatibility complex class II molecules,
the activity of nitric-oxide synthase, and the production of
proinflammatory cytokines (Xaus et al., 1999
).
In this report, a close interaction between cell surface ADA and the A2B adenosine receptor present on Jurkat J32 T cells and Chinese hamster ovary (CHO) cells transfected with the cDNA coding for the human A2BR, is demonstrated by ADA binding, confocal microscopy, and coimmunoprecipitation. Moreover, it is shown that this novel protein-protein interaction regulates the binding of agonists to A2BRs by increasing the ligand-binding affinity and the 5'-N-ethylcarboxamidoadenosine (NECA)-induced second messenger production.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Fluorescein isothiocyanate (FITC),
tetramethylrhodamine isothiocyanate (TRITC), saponin,
paraformaldehyde, bovine serum albumin, polyethylenimine (50%),
propidium iodide, NECA, and RNase were purchased from Sigma Chemical
Co. (St. Louis, MO). [3H]N-NECA (15.1 Ci/mmol)
was purchased from Perkin Elmer Life Sciences (Boston, MA).
Glycine and electrophoresis reagents were obtained from Boehringer
Mannheim (Barcelona, Spain). Nonidet P-40 was from Calbiochem (La
Jolla, CA). Sephadex G-25 fine grade columns and protein A-Sepharose
CL-4B were obtained from Amersham Pharmacia Biotech (Uppsala, Sweden).
Deionized water further purified with a Millipore Milli-Q system
(Bedford, MA) was used throughout. Bovine ADA (type VIII, 200 IU/mg of
protein; Sigma), filtered through Sephadex G-25, was used before all
assays. Bovine ADA activity (30 IU/ml) was completely abolished by
preincubation with 0.1 mM HgCl2 (2 h); removal of
free Hg2+ was accomplished by gel filtration
using Sephadex G-25 (Ciruela et al., 1996
).
Cells and Transfections.
Chinese hamster ovary (CHO) cells
stably transfected with cDNA coding for the human
A2BR have been previously characterized (Pierce
et al., 1992
). CHO cells stably transfected with cDNA coding for the
human dopamine D2 receptor were kindly provided by Dr. Kjell Fuxe
(Karolinska Institutet, Stockholm, Sweden). Transfected CHO cells were
grown in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 (1:1)
(Life Technologies, Inc., Gaithersburg, MD) containing 10% fetal calf
serum, 2 mM L-glutamine, antibiotics (100 U/ml penicillin,
100 µg/ml streptomycin, and 0.25 µg/ml Fungizone), and a 1.6 mg/ml
concentration of the neomycin analog G418. Wild-type CHO cells were
cultured in the same conditions described for transfected cells but in
the absence of G418. For transient expression, HEK 293 cells were used.
Cells growing in 75-cm3 dishes were transiently
transfected with 10 µg of DNA encoding for human metabotropic
glutamate receptors mGluR1
or mGluR1
by calcium phosphate
precipitation (Jordan et al., 1996
). Cells were grown in DMEM
supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine,
100 U/ml penicillin/streptomycin, and 10% (v/v) fetal calf serum
(37°, 5% CO2). Cells were harvested 48 h
after transfection.
Antibodies.
Rabbit anti-ADA antibody (Serotek, Oxford, UK)
has been developed in our laboratory previously (Arán et al.,
1991
). The antibody against A2B receptor, MPE1,
is an affinity-purified (chromatographed through specific peptide
coupled to Sepharose) version of the antipeptide antisera ME developed
and characterized as described elsewhere (Mirabet et al., 1999
). The
fluorescein-conjugated anti-CD26 monoclonal antibody (mAb) Ta1 was from
Coulter Clone (Izasa, Barcelona, Spain). Affinity-purified polyclonal
antibody F1 against an extracellular epitope of metabotropic mGluR1 was
characterized elsewhere (Ciruela and McIlhinney, 1997
). Polyclonal
antibodies against human D2 dopamine receptors were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA). The fluorescein-conjugated
rabbit IgG was from Sigma, and donkey anti-rabbit IgG-peroxidase was
from Boehringer Mannheim.
Protein Content Determination and Conjugation to
Fluorochromes.
Protein was quantified by the bicinchoninic acid
method (Pierce Chemical Co., Rockford, IL) as described by Sorensen and
Brodbeck (1986)
and using bovine serum albumin as standard. Antibodies and the enzyme ADA were conjugated to fluorescein isothiocyanate or
tetramethylrhodamine isothiocyanate as described elsewhere (Mirabet et
al., 1999
).
Immunostaining Assays and Cell Sorting.
Transfected or
wild-type CHO cells and transfected HEK 293 cells, grown on glass
coverslips, and peripheral blood lymphocytes or Jurkat J32 cells
(4 × 106) were fixed with 2% (w/v)
paraformaldehyde and stained as described by Mirabet et al. (1999)
.
When necessary, cells were fixed and permeabilized adding 0.05%
saponin for CHO cells or 0.2% Triton for HEK 293 cells (included in
the fixation solution). For nuclear staining with propidium iodide,
cells were incubated with 50 µl of 5 µg/ml propidium iodide and 2 µg/ml RNase for 1 min at room temperature. For confocal microscopy
analysis, a Leica TCS 4D confocal scanning laser microscope adapted to
an inverted Leitz DMIRBE microscope (Leica Lasertechnik GmbH,
Heidelberg, Germany) was used. The colocalization analysis was made by
means of Multi Color software (version 2.0; Leica Lasertechnik GmbH).
Flow cytometry analysis was done using an EPICS Profile flow cytometer
(Coulter, Hialeah, FL). The parameters used to select cell populations
for analysis were forward and side light scattering. Cell sorting was
performed using the EPICS Profile equipment. For this purpose, Jurkat
J32 cells were fixed and labeled with Ta1-FITC anti-CD26 mAb to select
CD26
cells. A minimum number of 250,000 lymphocytes were selected, recovered in PBS, and processed for further analysis.
125I-Labeled ADA Binding. Bovine ADA was iodinated by using the Bolton-Hunter reagent (Amersham Pharmacia Biotech) according to the instructions of the supplier.
For 125I-labeled ADA binding, cells were washed twice with PBS buffer and suspended at 3 × 105 cells/ml. Aliquots were incubated for 2 h with 125I-ADA in the presence or absence of unlabeled ADA in a final volume of 300 µl. Then cells were washed in cold PBS, resuspended in 0.2% SDS, and placed in 10-ml vials containing Formula 989 mixture. Vials were shaken overnight and counted using a 1600 Tri-Carb scintillation counter (Packard Instrument Co., Inc., Meriden, CT) with 50% efficiency.Ligand Binding Experiments.
Membrane suspensions from
A2B-transfected CHO cells were obtained according
to Casadó et al. (1990)
. 38 nM [3H]NECA
binding to membrane suspensions (0.5 mg of protein/ml) were carried out
at 25°C in 50 mM Tris-HCl buffer, pH 7.4, in the absence or presence
of the indicated amount of ADA. After 2 h of radioligand
incubation, free and membrane-bound radioligand were separated by rapid
filtration of 500-µl aliquots in a Brandel (Gaithersburg, MD) cell
harvester through Whatman (Clifton, NJ) GF/C filters embedded in
polyethyleneimine. Nonspecific binding was defined as the binding
remaining in the presence of an excess of displacer (100 µM NECA).
For competition experiments radioligand binding was performed as
described above in the presence of increasing amounts of NECA. Filters
were transferred to scintillation vials containing 10 ml of Formula 989 (Perkin Elmer Life Sciences). Radioactivity was counted using a Packard
1600 Tri-Carb scintillation counter with 50% of efficiency. In all
cases five replicates of each point were performed. Competition data
were fitted using a nonlinear regression program as previously
described (Casadó et al., 1990
, 1992
).
Immunoprecipitation and Immunoblotting.
Cell extracts and
cell membranes were obtained as described by Ciruela et al. (1999)
.
Cell membranes were solubilized (Ciruela et al., 1999
) and
immunoprecipitated with anti-ADA, or irrelevant rabbit anti-goat IgG
antibodies covalently coupled to a protein A matrix (Schneider et al.,
1982
) (4°C, overnight). Each immunoprecipitate was washed and
resuspended in 60 µl of SDS-polyacrylamide gel electrophoresis
nonreducing sample buffer (0.125 M Tris-HCl, pH 6.8, 4% SDS,
20% v/v glycerol, 0.02% bromphenol blue). Samples were heated 15 min
at 37°C, and after centrifugation at 1200g, immunoprecipitated proteins were resolved by SDS-polyacrylamide gel
electrophoresis in 7.5% gels (Laemmli, 1970
). Immunoblotting was
performed using the anti-ADA antibody (10 µg/ml) or the
anti-A2BR MPE1 antibody (2 µg/ml) and
anti-rabbit IgG-peroxidase (Boehringer Mannheim). Polyvinyl difluoride
membranes (Immobilon-P; Millipore) were incubated in equal volumes of
SuperSignal Chemiluminescent substrates 1 and 2 (Pierce Chemical Co.).
The detection reagent was drained off, and the filters were placed in
contact with a film (Hyperfilm ECL), which was developed by chemiluminescence.
cAMP Determination. A2B-transfected CHO cells were grown as confluent monolayers in 24-well cluster dishes (approximately 130,000 cells/well). Cells were washed five times with 2.5 ml of Hanks' balanced salt solution buffer (140 mM NaCl, 5 mM KCl, 1 mM magnesium chloride, 1 mM magnesium sulfate, 1.2 mM calcium chloride, 10 mM HEPES, 5 mM glucose, 0.3 mM potassium dihydrogen phosphate, and 2 mM sodium hydrogen phosphate), pH 7.2 at 37°C. Cells were then incubated (15 min at 37°C) in 0.4 ml of Hanks' balanced salt solution buffer containing 30 µM cAMP phosphodiesterase inhibitor RO-20-1724 (Calbiochem); when included, the concentration of ADA was 0.5 U/ml. cAMP production was induced by addition of 1 µM NECA. After 15 min in the presence of the ligand, reaction was stopped by diluting with 2 volumes of cold ethanol. Samples were centrifuged at 2000g for 15 min at 4°C, and the supernatants were transferred to a clean tube. Samples were dried by gassing with nitrogen at 60°C, and the pellets were resuspended in water. cAMP was quantified by use of an enzyme immunoassay kit from Amersham Pharmacia Biotech following the manufacturer's protocol without acetylation.
| |
Results |
|---|
|
|
|---|
Expression of ADA on the Cell Surface of CHO Cells Overexpressing
A2BRs.
The FITC-MPE1 antibody, which specifically
recognizes an extracellular epitope of A2BR, was
used to detect the expression of these receptors in CHO cells
transfected with the cDNA coding for the human receptor
(CHO-A2B). Parental CHO cells could not be
labeled with the MPE1 antibody (Fig. 1A),
whereas CHO-A2B cells showed a marked staining
(Fig. 1C, in green). Parental CHO cells had cytoplasmic ADA, which was
detected using permeabilized cells, but did not express cell surface
ADA (Fig. 1B). However, when functional A2BR was
overexpressed in CHO cells, cell surface ADA could be detected (Fig.
1C, in red) and the analysis by confocal microscopy demonstrated a very
high degree of colocalization (in yellow) between ADA (red
fluorescence) and A2BR (green fluorescence). This
colocalization indicates that ADA and A2BR are
close on the surface of transfected cells. Binding of FITC-conjugated
ADA to parental CHO cell surface could not be detected by confocal
microscopy (Fig. 2A), but was readily
measurable in the case of with CHO-A2B cells
(Fig. 2B). To quantify the binding of ADA to the surface of
CHO-A2B cells, we used
125I-labeled ADA. As shown in Fig. 2C, the
binding of 125I-ADA was dose-dependent and
saturable.
|
|
Colocalization of Cell Surface ADA and A2BR in T
Lymphocytes.
To know whether these results obtained in a
heterologous model are physiologically relevant, the localization of
the cell surface ADA and the A2BR was studied in
human cells expressing the two molecules. Jurkat J32 T lymphocytes
naturally express the two proteins but also express CD26, which is an
ADA-anchoring protein (see the introduction). The labeling of Jurkat
J32 cells (Fig. 3A) with
FITC-anti-A2BR MPE1 (green fluorescence) and
TRITC-anti-ADA (red fluorescence) indicated a high degree of
colocalization (in yellow) between ADA and A2BR.
As reported previously, there was also a high degree of colocalization
between ADA (detected with TRITC-anti-ADA, red fluorescence) and CD26
(detected with FITC-Ta1 mAb, green fluorescence) in Jurkat J32 cells
(Fig. 3B). The distribution of ADA, CD26, and
A2BR in cells was studied by flow cytometry. ADA+ Jurkat J32 cells were heterogenous, because
there were ADA+CD26+ and
also ADA+CD26
cells.
These results are in agreement with the existence of
ADA+CD26
cells in
peripheral blood lymphocytes (data in preparation). To analyze whether
A2BR were expressed in
ADA+CD26
cells, a sorting
procedure was devised. Jurkat J32 cells were stained with the
FITC-conjugated Ta1, and only CD26
cells were
selected. The sorted cells were analyzed by confocal microscopy to
confirm that no CD26 was expressed. These CD26
cells were then labeled with FITC-MPE1 and TRITC-anti-ADA. Confocal microscopy images showed that cell surface ADA colocalized with A2BRs in
ADA+CD26
-sorted cells
(Fig. 3C).
|
|
|
receptors and adenosine A1 receptors are
coupled to phospholipase C. Although the cells transfected with the
cDNA for all these receptors contain ADA in the cytoplasm, ADA is not
expressed on the surface of the transfected cells (Fig.
6).
|
Effect of ADA upon NECA Binding to A2BR and upon
NECA-Induced cAMP Production.
The effect of ADA upon the binding
of NECA to A2BR was analyzed by means of
radioligand binding assays as described under Materials and
Methods. The binding of [3H]NECA to
CHO-A2BR cells was enhanced in a dose-dependent
fashion by exogenous ADA (Fig. 7A). This
enhancement was similar when ADA, devoid of enzymatic activity, was
used. This indicates that the effect is caused by the interaction with
A2BR rather than an inactivation of endogenous
adenosine, which could be present in the preparation. In displacement
experiments performed in the presence and absence of ADA, it is shown
that ADA leads to a reduction (from 2.1 ± 0.5 to 0.4 ± 0.1 µM) in the Ki value for unlabeled NECA
(Fig. 7B) without affecting the unspecific binding. Therefore, the
affinity of NECA for A2BR in transfected
CHO-A2BR cells increases when ADA interacts with
the receptor. In agreement to this potentiation in the NECA binding,
ADA led to a 36% increase in the NECA-induced cAMP levels (Fig. 7C).
|
| |
Discussion |
|---|
|
|
|---|
Cell surface ADA needs to be anchored to the plasma membrane by
means of specific receptors. In lymphocytes, CD26 has been described as
an ADA-anchoring protein. In nonlymphoid cells it has been reported
that A1 adenosine receptors can anchor ADA to the
cell surface. Both ADA/CD26 and ADA/A1R
interactions are functionally important, as ADA/CD26 have a
costimulatory role in the lymphocytes and ADA facilitates ligand
binding to A1R and regulates signal transduction
(Franco et al., 1997a
,b
). In this article, we report a third protein
able to interact with ADA on the cell surface, the
A2BR. The use of CHO cells transfected with the
human cDNA for the A2BR was important to
demonstrate the differences between the interactions of ADA/CD26 and
ADA/A2BR. Wild-type CHO cells express hamster
CD26, and it is well-reported (Dong et al., 1997
) that rodent CD26 is
unable to bind ADA (either human or rodent ADA). Therefore, cell
surface ADA cannot be detected in CHO cells despite the fact that these
cells have cytoplasmic ADA. This is also why wild-type CHO cells
are a good negative control for cell surface ADA expression. When the
human A2BR is expressed in these cells, ADA
appears on the cell surface, because it can bind to this anchoring
protein. It should be noted that we find colocalization between ADA and
A2BR in human lymphocytes and that bovine ADA can
be bound to human A2BR. These results indicate
that human A2BR is able to interact with human,
bovine, and hamster ADA. It has been demonstrated that CD26 does not
participate in the transport of ADA toward the cell surface but anchors
ADA after the protein has been released from homologous or heterologous cells (Dong et al., 1996
). The fact that we find no differences in the
level of ADA exported toward the medium in parental and CHO-A2BR cells (not shown) suggest that ADA is
released from the cell by a mechanism also independent of the
expression of A2BR and, afterwards, it is bound
to the ADA-anchoring protein.
Apart from these CD26, A1R, and
A2BR proteins, which behave as cell surface
receptors for ADA, ADA is able to interact in the cytoplasm with the
Grb2 isoform Grb3-3 (Ramos-Morales et al., 1997
). Grb2 plays an
essential role in cell growth and differentiation by connecting
tyrosine kinase receptors to activation of the Ras pathway. Grb3-3 is a
naturally occurring isoform of Grb2 that carries a 41-amino acid
deletion in the SH2 domain, which abolishes the binding to
tyrosine-phosphorylated proteins but retains functional SH3 domains,
which allow interaction with other proteins through binding to
proline-rich sequences. Grb3-3 may be involved in apoptosis (Fath et
al., 1994
), but the role of this molecule has not been fully
elucidated. The variety of interactions in which ADA participates can
be explained from a structural point of view. The three-dimensional structure, which is known for the murine enzyme expressed in
Escherichia coli (Wilson et al., 1991
), indicates that ADA
possesses several hydrophobic zones that are unusual for soluble
enzymes and that are likely involved in different protein-protein
interactions [see Franco et al. (1997b)
for review].
There is some controversy related to the percentage of cells expressing
ADA on the cell surface of human lymphocytes and of human T cell lines.
The expression of cell surface ADA is usually determined by incubation
with anti-ADA antibodies before fixation of the cells (Kameoka et al.,
1993
; Martín et al., 1993
, 1995a
,b
; De Meester et al., 1994
;
Dong and Morimoto, 1996
; Dong et al., 1996
, 1997
; Morimoto and
Schlossman, 1998
). Fixation before incubation with antibodies is a key
step. The percentage of Jurkat J32 T cells expressing cell surface ADA
can be 20% if the incubation is performed in nonfixed cells or 100%
if fixed cells are treated with the antibodies. The use of fixed cells
has allowed us to detect
ADA+CD26
populations in
Jurkat J32 T cells (see Results). In this
ADA+CD26
population, ADA
is bound to the cell surface through A2BR. The relevance of the existence of these two different populations is at
present unknown. However, the fact that ADA and
A2BR are coordinately up-regulated in response to
activating signals indicates that both A2BR and
the ADA/A2BR interaction have a role in T cell activation. We have previously described how adenosine, acting through
A2BR, contributes to deactivation of macrophages,
because it reduces the up-regulation of major histocompatibility
complex class II molecules, the activity of nitric-oxide synthase or
the production of proinflammatory cytokines (Xaus et al., 1999
). In human lymphocytes, adenosine, acting through
A2BR, elicits a significant reduction in
interleukin-2 production (Mirabet et al., 1999
). The role of ADA bound
to A2BR, apart from degrading the extracellular adenosine, is to modulate the binding of agonists. In fact, the presence of ADA, irrespective of its catalytic activity, leads to an
increase in the affinity of NECA for A2BR (see
Fig. 7) and, accordingly, to an increase in the cAMP levels induced by
activation of A2BR. This is similar to what has
been reported for the ADA/A1R module in a smooth
muscle cell line (Ciruela et al., 1996
). There are no obvious
homologies between A2BR or
A1R and CD26, which is the third protein able to
anchor ADA to the cell surface. This suggests that the interaction of
ADA with CD26 or with A2BR or A1R occurs via different epitopes in the ADA
molecule [see Franco et al. (1997a)
for details on ADA epitopes].
| |
Acknowledgments |
|---|
We acknowledge the technical help received from Jaume Comas and M. del Rosario González (flow cytometry) and from Susana Castel (confocal microscopy section).
| |
Footnotes |
|---|
Received January 5, 2000; Accepted August 11, 2000
This research was supported by Spanish Comisión Interministerial de Ciencia y Tecnologia's Investigation and Development programs Salud y Farmacia (SAF97/0066) and Biotechnology (BIO1999/0601/C02).
Send reprint requests to: Prof. Rafael Franco, Dept. Bioquímica i Biologia Molecular, Universitat de Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain. E-mail: r.franco{at}sun.bq.ub.es
| |
Abbreviations |
|---|
SCID, severe combined immunodeficiency syndrome; ADA, adenosine deaminase; A2BR, adenosine A2B receptor; CHO, Chinese hamster ovary; NECA, 5'-N-ethylcarboxamidoadenosine; mAb, monoclonal antibody; FITC, fluorescein isothiocyanate; TRITC, tetramethylrhodamine isothiocyanate; DMEM, Dulbecco's modified Eagle's medium; HEK, human embryonic kidney; PHA, phytohemagglutinin; mAb, monoclonal antibody.
| |
References |
|---|
|
|
|---|
with Homer-1a/Vesl-1S increases the cell surface expression of the receptor.
Biochem J
341:
795-803.
up-regulates the A2B adenosine receptor expression in macrophages: A mechanism of macrophage deactivation.
J Immunol
162:
3607-3614This article has been cited by other articles:
![]() |
X. Hua, M. Kovarova, K. D. Chason, M. Nguyen, B. H. Koller, and S. L. Tilley Enhanced mast cell activation in mice deficient in the A2b adenosine receptor J. Exp. Med., January 22, 2007; 204(1): 117 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Eltzschig, M. Faigle, S. Knapp, J. Karhausen, J. Ibla, P. Rosenberger, K. C. Odegard, P. C. Laussen, L. F. Thompson, and S. P. Colgan Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26 Blood, September 1, 2006; 108(5): 1602 - 1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Willems, M. E. Reichelt, J. G. Molina, C.-X. Sun, J. L. Chunn, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts Cardiovasc Res, July 1, 2006; 71(1): 79 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ciruela, V. Casado, R. J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N. Rebola, S. R. Goldberg, J. Mallol, et al. Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers J. Neurosci., February 15, 2006; 26(7): 2080 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pacheco, J. M. Martinez-Navio, M. Lejeune, N. Climent, H. Oliva, J. M. Gatell, T. Gallart, J. Mallol, C. Lluis, and R. Franco CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse PNAS, July 5, 2005; 102(27): 9583 - 9588. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Aldinucci, D. Poletto, D. Lorenzon, P. Nanni, M. Degan, K. Olivo, B. Rapana, A. Pinto, and V. Gattei CD26 Expression Correlates with a Reduced Sensitivity to 2'-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas Clin. Cancer Res., January 15, 2004; 10(2): 508 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons Pharmacol. Rev., September 1, 2003; 55(3): 509 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Sitaraman, L. Wang, M. Wong, M. Bruewer, M. Hobert, C-H. Yun, D. Merlin, and J. L. Madara The Adenosine 2b Receptor Is Recruited to the Plasma Membrane and Associates with E3KARP and Ezrin upon Agonist Stimulation J. Biol. Chem., August 30, 2002; 277(36): 33188 - 33195. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. Cordero, F. J. Salgado, C. M. Fernandez-Alonso, C. Herrera, C. Lluis, R. Franco, and M. Nogueira Cytokines regulate membrane adenosine deaminase on human activated lymphocytes J. Leukoc. Biol., December 1, 2001; 70(6): 920 - 930. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||